EMA’s CHMP recommends approval of Bristol Myers Squibb’s HCC treatment combo
The decision is based on outcomes from the Phase III CheckMate -9DW trial. According to the outcomes of the trial presented by the company in June last year,
DEBRA Research and LEO Pharma have announced a non-exclusive strategic collaboration aiming to improve scouting capabilities and offer extra capacity to propel the development of therapies for Epidermolysis Bullosa (EB).
Sanofi Ventures and EQT Life Sciences jointly led the funding round. New investors like Novartis Venture Fund, RiverVest Venture Partners, Mirae Asset Financial Group, abrdn-managed funds, GHR Foundation,